Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.

ABSTRACT:

Background

Glucagon-like peptide-1 (GLP-1) receptor agonists, including a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist, have expanded treatment options for overweight and obesity. However, real-world data within Medicaid populations remain limited.

Objective

To assess 6-month persistence, adherence, and effectiveness of GLP-1 and GLP-1/GIP therapies among Massachusetts Medicaid (MassHealth) members.

Methods

This retrospective, claims-based analysis identified continuously enrolled MassHealth adults, with or without diabetes, initiating GLP-1 or GLP-1/GIP treatment with semaglutide (Wegovy) or tirzepatide (Zepbound) between July 1, 2024, and December 31, 2024. The co-primary outcomes were persistence, defined as no more than 56 days between fil

SUBMITTER: Meyer KB 

PROVIDER: S-EPMC12948758 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature